美常安与马来酸曲美布汀治疗腹泻型肠易激综合征的疗效

目的评价美常安和马来酸曲美布汀(舒丽启能)对腹泻型肠易激综合征(IBS)的疗效。方法将86例确诊为腹泻型IBS患者随机分成A组30例(服美常安500mg,tid)、B组28例(服马来酸曲美布汀0.2g,tid)和C组28(服美常安+马来酸曲美布汀,剂量同前)。疗程14d,观察治疗前后患者的症状、排便次数、粪便性状。结果3d症状改善率B组、C组优于A组(P<0.05)。A组和B组疗程结束总有效率分别为83.3%和82.1%,C组达96.4%,总有效率C组明显优于A组和B组(P<0.05)。停药4周内复发率A、B、C组分别为16.7%,32.1%,14.3%,A组和C组明显少于B组(P<0.01)。结论美常安和马来酸曲美布汀对腹泻型IBS均有效,马来酸曲美布汀见效快,美常安疗效持久。联合应用美常安与马来酸曲美布汀可取长补短,对腹泻型IBS可达到止泻快且不易复发的疗效。

The Effect of Combination of Medilac-S with Trimebutine Maleate in Patients with Diarrhea-predominant Irritable Bowel Syndrome

Objective To evaluate the efficacy of combination of Medilac-s with Trimebutine Maleate for diarrhea-predominant irritable bowel syndrome（IBS）. Methods 86 patients with diarrhea-predominant IBS were randomized to receive one of three treatment regimens： Medilac-s alone （500mg,tid,n =32）in group A or Trimebutine Maleate alone （0.2g,tid,n = 28） in group B or Medilac-s 500mg plus Trimebutine Maleate 0.2g （tid,n = 26） in group C. Each patient was treated for 14 days. Results The response rates at 3 days in group B and C were significantly higher than those in group A, （P〈0.05）. The total effective rates of group A, B and C at 14 days were 83.3%, 82.1% and 96.4%, respectively. The total effective rates in group C were higher than those in group B and C （P〈0.05）. The recurrence rates of group A,B and C within 4 weeks after therapy were 16.7%, 32.1% and 14.3%, respectively and those of group B and C were much less than those of group A （P〈 0.01 ）. Conclusion Both Medilac-s and Trimebutine Maleate are effective in treating diarrhea-predominant IBS. Combination of Medilac-s with Trimebutine Maleate offered effective and lasts improvement for patients with diarrhea -predominant IBS.